DK2134339T3 - Præparater, der omfatter (s)-2-amino-1-(4-chlorphenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol som modulator af proteinkinaser - Google Patents
Præparater, der omfatter (s)-2-amino-1-(4-chlorphenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol som modulator af proteinkinaserInfo
- Publication number
- DK2134339T3 DK2134339T3 DK08719025.2T DK08719025T DK2134339T3 DK 2134339 T3 DK2134339 T3 DK 2134339T3 DK 08719025 T DK08719025 T DK 08719025T DK 2134339 T3 DK2134339 T3 DK 2134339T3
- Authority
- DK
- Denmark
- Prior art keywords
- chlorphenyl
- pyrazol
- modulator
- phenyl
- ethanol
- Prior art date
Links
- IIRWNGPLJQXWFJ-KRWDZBQOSA-N (1s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)phenyl]ethanol Chemical compound C1([C@](O)(CN)C=2C=CC(=CC=2)C2=CNN=C2)=CC=C(Cl)C=C1 IIRWNGPLJQXWFJ-KRWDZBQOSA-N 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
- C07C215/32—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
- C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89475207P | 2007-03-14 | 2007-03-14 | |
| GBGB0704932.3A GB0704932D0 (en) | 2007-03-14 | 2007-03-14 | Pharmaceutical compounds |
| PCT/GB2008/050180 WO2008110846A2 (en) | 2007-03-14 | 2008-03-14 | Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2134339T3 true DK2134339T3 (da) | 2014-11-03 |
Family
ID=38008428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08719025.2T DK2134339T3 (da) | 2007-03-14 | 2008-03-14 | Præparater, der omfatter (s)-2-amino-1-(4-chlorphenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol som modulator af proteinkinaser |
Country Status (23)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2228369A1 (en) | 2003-12-23 | 2010-09-15 | Astex Therapeutics Ltd. | Pyrazole derivatives as protein kinase modulators |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2006136837A2 (en) | 2005-06-23 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2010083283A2 (en) | 2009-01-15 | 2010-07-22 | Incyte Corporation | Processes for preparing jak inhibitors and related intermediate compounds |
| CN106456631A (zh) * | 2014-03-06 | 2017-02-22 | 南加利福尼亚大学 | 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用 |
| RU2657832C1 (ru) * | 2017-06-07 | 2018-06-15 | федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" | Антидиабетическое средство |
| EP3424533A1 (en) * | 2017-07-05 | 2019-01-09 | Nh Theraguix | Methods for treating tumors |
| US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
| CA3169944A1 (en) * | 2020-03-25 | 2021-09-30 | Thomas Macallister | Methods of using rho kinase inhibitors to treat frontotemporal dementia |
| CN111707830B (zh) * | 2020-07-16 | 2023-08-15 | 首都医科大学附属北京朝阳医院 | Rock激酶活性在辅助诊断肺损害中的应用 |
| AU2020480829A1 (en) | 2020-12-07 | 2023-07-20 | Kimberly-Clark Worldwide, Inc. | Methods and consumer products for detecting a metabolite |
| AU2024292342A1 (en) | 2023-07-17 | 2026-02-26 | Graviton Bioscience Bv | Formulations and uses of rock2 inhibitors for als |
| IL327381A (en) | 2023-09-28 | 2026-05-01 | Graviton Pharmaceuticals B V | Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors |
| IL327385A (en) | 2023-09-29 | 2026-05-01 | Graviton Pharmaceuticals B V | ROCK2 inhibitors in the treatment of obesity |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| WO1990009381A1 (en) | 1989-02-08 | 1990-08-23 | Abbott Laboratories | 4-hydroxythiazoles as 5-lipoxygenase inhibitors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5049570A (en) | 1990-01-23 | 1991-09-17 | Du Pont Merck Pharmaceutical Company | Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity |
| FR2707295A1 (fr) | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US5532356A (en) | 1995-06-06 | 1996-07-02 | The Dupont Merck Pharmaceutical Company | Method for preparing N,N'-disubstituted cyclic ureas |
| GB9512961D0 (en) | 1995-06-26 | 1995-08-30 | Pfizer Ltd | Antifungal agents |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2249645A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| GB2339298B (en) | 1996-04-30 | 2000-05-10 | Eastman Kodak Co | Use of pyrazolone image dye-forming couplers for enhancing light stability |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| GB9700555D0 (en) | 1997-01-13 | 1997-03-05 | Merck Sharp & Dohme | Therapeutic agents |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
| CN1289248A (zh) | 1998-01-29 | 2001-03-28 | 维洛药品公司 | 治疗或预防肺病毒感染及有关疾病的化合物、组合物和方法 |
| GB9804734D0 (en) | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
| DE69935335T2 (de) | 1998-08-07 | 2007-11-22 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Pyrazole als modulatoren des östrogenrezeptors |
| HN1999000149A (es) | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
| US6503905B1 (en) | 1998-12-29 | 2003-01-07 | Pfizer Inc | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| WO2000066562A1 (en) | 1999-05-03 | 2000-11-09 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
| EP1185530A1 (en) | 1999-05-14 | 2002-03-13 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| AU781880B2 (en) | 1999-09-17 | 2005-06-16 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| US6511994B2 (en) | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
| JP2004538266A (ja) | 2001-04-27 | 2004-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール由来のキナーゼインヒビター |
| US6750239B2 (en) | 2001-08-03 | 2004-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
| FR2830192B1 (fr) | 2001-09-28 | 2004-08-20 | Oreal | Composition tinctoriale comprenant une base d'oxydation du type diaminopyrazole et un coupleur pyrazolo-azole |
| WO2003048081A2 (en) | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| MXPA04009040A (es) | 2002-03-20 | 2005-01-25 | Metabolex Inc | Acidos fenilaceticos sustituidos. |
| EP1492477B1 (en) | 2002-04-08 | 2016-04-13 | Boston Scientific Scimed, Inc. | Satiation devices and methods |
| AU2003223708A1 (en) | 2002-04-23 | 2003-11-10 | Axys Pharmaceuticals, Inc. | Novel phenyl derivatives as inducers of apoptosis |
| EP1542997B1 (en) | 2002-07-24 | 2012-02-29 | Dermira (Canada), Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
| MXPA05002983A (es) | 2002-09-18 | 2005-06-22 | Univ Missouri | Analogos de opiato selectivos del receptor opioide d. |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| EP1644365A2 (en) | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| TWI344961B (en) | 2003-10-15 | 2011-07-11 | Ube Industries | Novel indazole derivative |
| WO2005048953A2 (en) | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
| EP1692112A4 (en) | 2003-12-08 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS, AND METHODS |
| EP2228369A1 (en) | 2003-12-23 | 2010-09-15 | Astex Therapeutics Ltd. | Pyrazole derivatives as protein kinase modulators |
| GB0329617D0 (en) * | 2003-12-23 | 2004-01-28 | Astex Technology Ltd | Pharmaceutical compounds |
| RU2419612C2 (ru) * | 2003-12-23 | 2011-05-27 | Астекс Терапьютикс Лимитед | Производные пиразола в качестве модуляторов протеинкиназы |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| AU2005322085B2 (en) | 2004-12-28 | 2012-07-19 | Exelixis, Inc. | [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| EP1919875A2 (en) | 2005-06-21 | 2008-05-14 | Astex Therapeutics Limited | Pyrazole derivatives and their use as pka and pkb modulators |
| GB2427406A (en) | 2005-06-21 | 2006-12-27 | Astex Technology Ltd | Silicon-containing PKB/PKA kinase inhibitors |
| UY29610A1 (es) * | 2005-06-21 | 2007-01-31 | Cancer Rec Tech Ltd | Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2006136837A2 (en) * | 2005-06-23 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
-
2007
- 2007-03-14 GB GBGB0704932.3A patent/GB0704932D0/en not_active Ceased
-
2008
- 2008-03-14 BR BRPI0808802A patent/BRPI0808802A2/pt not_active IP Right Cessation
- 2008-03-14 AU AU2008224657A patent/AU2008224657B2/en not_active Ceased
- 2008-03-14 NZ NZ579341A patent/NZ579341A/xx not_active IP Right Cessation
- 2008-03-14 DK DK08719025.2T patent/DK2134339T3/da active
- 2008-03-14 PT PT87190252T patent/PT2134339E/pt unknown
- 2008-03-14 WO PCT/GB2008/050180 patent/WO2008110846A2/en not_active Ceased
- 2008-03-14 EP EP11194939A patent/EP2433632A1/en not_active Withdrawn
- 2008-03-14 KR KR1020097020516A patent/KR20100014720A/ko not_active Ceased
- 2008-03-14 RU RU2009137779/04A patent/RU2527151C2/ru not_active IP Right Cessation
- 2008-03-14 ES ES08719025.2T patent/ES2511817T3/es active Active
- 2008-03-14 MX MX2009009874A patent/MX2009009874A/es active IP Right Grant
- 2008-03-14 CN CN200880015813.0A patent/CN101686965B/zh not_active Expired - Fee Related
- 2008-03-14 HR HRP20141034AT patent/HRP20141034T1/hr unknown
- 2008-03-14 SI SI200831312T patent/SI2134339T1/sl unknown
- 2008-03-14 JP JP2009553222A patent/JP2010521446A/ja active Pending
- 2008-03-14 US US12/531,013 patent/US20100113551A1/en not_active Abandoned
- 2008-03-14 PL PL08719025T patent/PL2134339T3/pl unknown
- 2008-03-14 EP EP08719025.2A patent/EP2134339B1/en active Active
- 2008-03-14 RS RSP20140587 patent/RS53580B1/sr unknown
- 2008-03-14 CA CA002679878A patent/CA2679878A1/en not_active Abandoned
-
2009
- 2009-09-08 IL IL200822A patent/IL200822A/en not_active IP Right Cessation
- 2009-09-10 ZA ZA2009/06303A patent/ZA200906303B/en unknown
-
2011
- 2011-07-11 US US13/180,127 patent/US8497294B2/en not_active Expired - Fee Related
-
2014
- 2014-08-25 JP JP2014170885A patent/JP2015028033A/ja active Pending
- 2014-11-12 CY CY20141100938T patent/CY1115877T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2433632A1 (en) | 2012-03-28 |
| AU2008224657B2 (en) | 2014-06-26 |
| EP2134339B1 (en) | 2014-09-17 |
| KR20100014720A (ko) | 2010-02-10 |
| PT2134339E (pt) | 2014-11-03 |
| ES2511817T3 (es) | 2014-10-23 |
| RU2527151C2 (ru) | 2014-08-27 |
| RU2009137779A (ru) | 2011-05-10 |
| JP2015028033A (ja) | 2015-02-12 |
| WO2008110846A2 (en) | 2008-09-18 |
| CY1115877T1 (el) | 2017-01-25 |
| AU2008224657A1 (en) | 2008-09-18 |
| JP2010521446A (ja) | 2010-06-24 |
| MX2009009874A (es) | 2009-09-24 |
| EP2134339A2 (en) | 2009-12-23 |
| US20100113551A1 (en) | 2010-05-06 |
| US20110269808A1 (en) | 2011-11-03 |
| NZ579341A (en) | 2012-08-31 |
| IL200822A (en) | 2016-09-29 |
| HK1133828A1 (en) | 2010-04-09 |
| IL200822A0 (en) | 2010-05-17 |
| GB0704932D0 (en) | 2007-04-25 |
| CN101686965B (zh) | 2014-09-17 |
| HRP20141034T1 (hr) | 2014-12-19 |
| ZA200906303B (en) | 2015-08-26 |
| PL2134339T3 (pl) | 2015-04-30 |
| RS53580B1 (sr) | 2015-02-27 |
| WO2008110846A3 (en) | 2009-03-05 |
| CN101686965A (zh) | 2010-03-31 |
| BRPI0808802A2 (pt) | 2017-05-02 |
| CA2679878A1 (en) | 2008-09-18 |
| US8497294B2 (en) | 2013-07-30 |
| SI2134339T1 (sl) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1711481T3 (da) | Fremgangsmåde til fremstilling af 2-aminothiazol-5-aromatiske carboxamider som kinaseinhibitorer | |
| IL200822A0 (en) | Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases | |
| BRPI0720695A2 (pt) | Compostos e métodos para modulação de cinase, e indicações para estes | |
| BRPI0918586A2 (pt) | compostos, composições e métodos de uso dos mesmos para a modulação dos níveis de ácido úrico | |
| DK2164831T3 (da) | Fremgangsmåde til fremstilling af n-substituerede (3-dihalomethyl-1-methyl-pyrazol-4-yl)carboxamider | |
| DK2046724T3 (da) | Fremgangsmåde til fremstilling af (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
| DK2381965T3 (da) | Modulation af præ-mrna under anvendelse af splejsningsmodulerende oligonukleotider som terapeutiske midler til behandling af sygdom | |
| DK2384133T3 (da) | Fremgangsmåde til brygning af teblade indeholdt i en kapsel | |
| DK2147098T3 (da) | Anvendelse af proteinhydrolysater til stabilisering af metalloprotease-detergent-formuleringer | |
| DK2364293T3 (da) | Hidtil ukendte pyrazol-4-N-alkoxycarboxamider som mikrobiocider | |
| DK2010498T3 (da) | Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister | |
| BRPI0923500A2 (pt) | uso e composição farmacêutica compreendendo agonista ou modulador do receptor s1p, e kit. | |
| DK2952177T3 (da) | Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer | |
| BRPI0908380A2 (pt) | Interface de usuário para planejar designação de recursos | |
| BR112012005853A2 (pt) | aplicador automático para preparações farmacêuticas líquidas, particularmente para insulina | |
| EP2293700A4 (en) | DISPOSABLE COSMETICS PACKAGE | |
| PL2303891T3 (pl) | Pirazolo-chinazoliny jako modulatory aktywności kinaz białkowych | |
| DK2283024T3 (da) | 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer | |
| DK2004610T3 (da) | Fremstilling af eslicarbazepin og beslægtede forbindelser ved asymmetrisk hydrogenering | |
| DK2118292T3 (da) | Papillomavirus E2-polypeptid der anvendes til vaccination | |
| DK2167395T3 (da) | Hætte til tilberedning af drikkevarer | |
| BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
| BRPI0918463A2 (pt) | métodos para fabricar e para usar um instrumento endodôntico, e, instrumento endodôntico. | |
| DK2152879T3 (da) | RNA antagonistforbindelser til modulering af beta-catenin | |
| DK2094676T3 (da) | Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater |